Back to News
Market Impact: 0.3
NewAmsterdam Pharma Company N.V. Reports Third Quarter Financial Results and European Commission Approval
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
NewAmsterdam Pharma reported revenue of $19.2 million for the quarter ended September 30, 2026, up from $0.3 million in the year-earlier quarter. The increase was primarily attributed to recognition of certain regulatory milestone payments; the provided article text does not include further results or outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NAMS0.35
More News
- Stifel reiterates Buy on NewAmsterdam Pharma stock, $50 target
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings